Brainspark PLC
09 August 2005
FOR IMMEDIATE RELEASE
9 August 2005
BRAINSPARK PLC
('Brainspark' or the 'Company')
Grant of call option over the Company's shares in Infusion 2002 Limited
Further to the announcement on 3 August 2005, the Company announces that it has
agreed pursuant to an agreement signed today ('the Call Option Agreement') to
grant a call option (the 'Option') to AISoftware SpA ('AISoftware') over the
entire issued share capital of its wholly owned subsidiary, Infusion 2002
Limited ('Infusion').
Infusion holds a 16.2 per cent. investment in Advanced Computer Systems SpA
('ACS'), an Italian based software company, which is held at a book value of
£1.43 million. The exercise price of the Option is £1.43 million.
The Call Option Agreement is subject to a number of conditions including a
condition that, by 31 October 2005, Infusion will have no assets or liabilities
other than its investment in ACS. Infusion will transfer its other assets to
other members of the Company's group. The Company will provide an indemnity
against any liabilities of Infusion.
Pursuant to the Option, the Company will receive an initial non-refundable
payment of £300,000 (the 'Initial Payment') which will be satisfied by the
release by AISoftware and its group companies of all debts owed directly or
indirectly by the Company and Infusion.
A further payment of £1,130,000 (the 'Second Payment') is payable on exercise of
the Option to be satisfied, subject to the consent of AISoftware's shareholders
and appropriate provisions of the Italian Civil Code, by the issue of new
ordinary shares in AISoftware.
AISoftware is listed on the Nuovo Mercato of the Milan Stock Exchange. The Nuovo
Mercato in Milan has broadly similar status to AIM in London.
The Company may terminate the Option at any time prior to 31 July 2006 (when the
Option would otherwise expire) provided it repays the Initial Payment, together
with a further payment of £50,000. The Company has provided certain limited
warranties to AISoftware.
As Francesco Gardin is a director of the Company and AISoftware, the grant of
the Option to AISoftware by the Company is to be treated as a related party
transaction. The independent directors, having consulted the Company's nominated
adviser, consider that the grant of the Option to AISoftware by the Company is
fair and reasonable so far as shareholders are concerned.
The independent directors believe that the Option enables the Company to
discharge its entire indebtedness to AIS amounting to £300,000, as well as
providing the potential for a more liquid investment or cash should the Option
be exercised by AISoftware.
ENDS
Further information
David Meacher, Brainspark PLC 020 7843 9838
Roland Cornish, Beaumont Cornish Limited 020 7628 3396
This information is provided by RNS
The company news service from the London Stock Exchange
AGRILFEETEIAIIE
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.